MDM2
Showing 1 - 25 of 263
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Seattle
Not yet recruiting
- Lung Non-Squamous Non-Small Cell Carcinoma
- +3 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Sargramostim
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 11, 2022
Pancreatic Tumors, Solid Tumors, Biliary Tract Cancer Trial (BI 907828)
Not yet recruiting
- Pancreatic Neoplasms
- +2 more
- BI 907828
- (no location specified)
Aug 22, 2022
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 Trial
Not yet recruiting
- Anatomic Stage IB Breast Cancer AJCC v8
- +16 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Sargramostim
-
Seattle, Washington
- +1 more
Jul 27, 2022
HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer Trial in Seattle
Recruiting
- HER2 Negative Breast Carcinoma
- +6 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Laboratory Biomarker Analysis
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 18, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in United States (Milademetan, AZA)
Terminated
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
-
Duarte, California
- +4 more
Sep 14, 2021
Malignant Salivary Gland Cancer, Salivary Gland Cancer Trial in Tampa, Chicago, Ann Arbor (APG-115, Carboplatin)
Recruiting
- Malignant Salivary Gland Cancer
- Salivary Gland Cancer
-
Tampa, Florida
- +2 more
Feb 10, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Trial in United States
Suspended
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Cytarabine
- +2 more
-
Los Angeles, California
- +5 more
Dec 10, 2022
Prevention of Chemo-induced Myelosuppression Trial in Worldwide (ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500
Recruiting
- Prevention of Chemotherapy-induced Myelosuppression
- ALRN-6924
- TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
-
Tamarac, Florida
- +14 more
Jan 31, 2023
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer Trial in Nashville (Atezolizumab, Cobimetinib,
Terminated
- Stage III Breast Cancer
- +6 more
- Atezolizumab
- +2 more
-
Nashville, TennesseeVanderbilt-Ingram Cancer Center
Aug 10, 2021
Myeloma Trial in Houston (DS-3032b)
Terminated
- Myeloma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 13, 2019
Ulcerative Colitis Trial in Worldwide (Adalimumab)
Active, not recruiting
- Ulcerative Colitis
- Adalimumab
-
Orlando, Florida
- +15 more
Jan 20, 2022
Liposarcoma, Atypical Lipomatous Tumor Trial in Montpellier (Blood sampling)
Recruiting
- Liposarcoma
- Atypical Lipomatous Tumor
- Blood sampling
-
Montpellier, FranceInstitut du Cancer de Montpellier - Val d'Aurelle
Mar 11, 2022
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma Trial in United States (Navtemadlin, Radiation Therapy)
Recruiting
- Resectable Soft Tissue Sarcoma
- Soft Tissue Sarcoma
- Navtemadlin
- Radiation Therapy
-
Goodyear, Arizona
- +52 more
Jul 21, 2022
Glomerulonephritis, Membranous, antiPLA2R Positive Trial in Worldwide (MOR202)
Completed
- Glomerulonephritis, Membranous
- antiPLA2R Positive
-
Azusa, California
- +44 more
Dec 12, 2022
Focal Segmental Glomerulosclerosis (FSGS) Trial in Worldwide (PF-06730512)
Active, not recruiting
- Focal Segmental Glomerulosclerosis (FSGS)
-
Birmingham, Alabama
- +59 more
Aug 17, 2022
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (KRT-232, acalabrutinib)
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
-
Goshen, Indiana
- +44 more
Aug 3, 2022
SNPs in p53 and p53 Response Elements on Inflammatory Response
Completed
- HIV-1 Seropositive
- +3 more
-
Research Triangle Park, North CarolinaNIEHS Clinical Research Unit (CRU)
Jan 21, 2023
Engagement Patterns and Participation Trends Among Liposarcoma
Not yet recruiting
- Liposarcoma
-
San Francisco, CaliforniaPower Life Sciences
Sep 8, 2023